title: Intracameral antibiotics: Safety, efficacy, and preparation.
abstract: Endophthalmitis is a rare but potentially devastating complication of cataract surgery. This article presents an overview of endophthalmitis prophylaxis and the use of intracameral antibiotics. It highlights available intracameral antibiotics with respect to pharmacology, spectrum of activity, dosage and preparation, safety, and efficacy profiles, as well as toxic anterior segment syndrome risks to better define the potential use of these medications in the prevention of endophthalmitis.
  
  
  BACKGROUND
  Proprietary or commercial disclosures are listed after the references.
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada). Electronic address: rbragamele@rogers.com.
authors.forename: Rosa
authors.initials: R
authors.lastname: Braga-Mele
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada).
authors.forename: David F
authors.initials: DF
authors.lastname: Chang
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada).
authors.forename: Bonnie An
authors.initials: BA
authors.lastname: Henderson
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada).
authors.forename: Nick
authors.initials: N
authors.lastname: Mamalis
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada).
authors.forename: Audrey
authors.initials: A
authors.lastname: Talley-Rostov
authors.affiliation: From the University of Toronto, Toronto, Canada (Braga-Mele); University of California, San Francisco, San Francisco, CA (Chang); Tufts University School of Medicine, Boston, MA (Henderson); Moran Eye Centre, University of Utah, Salt Lake City, UT (Mamalis); Northwest Eye Surgeons, Seattle, WA (Talley-Rostov); Raghudeep Eye Clinic, Ahmedabad, India (Vasavada).
authors.forename: Abhay
authors.initials: A
authors.lastname: Vasavada
mesh_terms: D000867:Anterior Chamber / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002387:Cataract Extraction; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use; D009877:Endophthalmitis / Q000382:microbiology / Q000517:prevention & control*; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000517:prevention & control*; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000077266:Moxifloxacin; D004364:Pharmaceutical Preparations; D016896:Treatment Outcome; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D004364:Pharmaceutical Preparations; D014640:Vancomycin; D000077266:Moxifloxacin